secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001193125-25-051957
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q4 product revenue $0.3M, net loss $0.24/sh; YCANTH units up 12.3% sequentially
--------------------------------------------------------------------------------

- Q4 product revenue $0.3M (vs $1.9M in 2023); FY product revenue $6.6M (vs $4.7M) with $3.2M returns reserve.
- Q4 GAAP net loss $16.2M ($0.24/sh) vs $24.6M ($0.53/sh); FY loss $76.6M ($1.48/sh) vs $67.0M ($1.48/sh).
- YCANTH dispensed units 8,654 in Q4 (+12.3% QoQ); operating expenses cut ~50% after restructuring with $1.0M charge.
- Cash $46.3M at Dec 31; $8M Torii milestone upon Phase 3 common warts start and $25M Series A warrants could extend runway; GAAP raises going concern doubt.
- VP-315 Phase 2 shows 97% ORR and ~51% complete histological clearance; Phase 3 for common warts could begin mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525051957/0001193125-25-051957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525051957/d937567d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-051957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer